Companies › Renaissance Pharma
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Mar 2031.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| hu14.18K322A monoclonal anti-GD2 antibody | GD2 | Phase 2 | High-Risk Neuroblastoma | Mar 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07549321 | hu14.18K322A | Phase 2 | High-Risk Neuroblastoma | Oncology | Mar 2031 |
NanoEcho Syncromune Galecto Biotech VSPharmTech BPGbio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.